#USA #Los Angeles #Securities Fraud #Frank Cruz Law #Baxter International

Baxter International and Securities Fraud Allegations

Baxter International, Inc., a significant player in the healthcare industry and publicly traded under the ticker symbol BAX, is currently facing a class action lawsuit, as announced by the Law Offices of Frank R. Cruz. This lawsuit is particularly crucial for investors who have experienced financial losses associated with Baxter's performance. If you are one of these shareholders, you may have the opportunity to take a leading role in this legal action.

## Details of the Allegations
The core of the lawsuit revolves around claims that Baxter failed to disclose critical issues regarding its Novum LVP devices within a specific timeframe, from February 23, 2022, to July 30, 2025.

Allegations include:

• - Systemic Defects: The Novum LVP devices were purported to have systemic defects that led to severe malfunctions, including risks of overinfusion, underinfusion, and even the complete non-delivery of fluids to patients. Such issues present significant danger, risking serious injury or death to those relying on these medical devices.
• - Awareness of Malfunctions: It is alleged that Baxter was aware of multiple cases of device malfunctions, injuries, and fatalities linked to these defects.
• - Inadequate Responses: The company's efforts to rectify these problems, primarily through customer alerts, were reportedly insufficient to address the ongoing design flaws, which continued to jeopardize patient safety.
• - Business Impact: As concerns mounted, it was anticipated that customers might choose to remove existing Novum LVP devices from service altogether. Consequently, there was a heightened risk that Baxter would cease new sales of the impaired pumps.
• - Misleading Information: The defendants’ optimistic statements regarding Baxter’s operations and future prospects have been described as materially misleading, lacking any reasonable basis, which has contributed to the shareholders' losses.

What Should Investors Do?

For investors who have suffered losses in connection with Baxter International, the lead plaintiff deadline is approaching on December 15, 2025. It is crucial for affected shareholders to act promptly to protect their rights and possibly recover losses endured as a result of these alleged actions by Baxter.

How to Participate

If you have questions or wish to participate in this class action, you can reach out to the Law Offices of Frank R. Cruz for more information. They can provide further details about the legal proceedings and guide you through the process:

• - Email: mailto:[email protected]
• - Phone: 310-914-5007
• - Website: frankcruzlaw.com

Investors don’t need to take any immediate action to be included in the class and may decide to hire an attorney of their choice or remain passive members of the lawsuit. It is also advised to share your purchase details and contact information if you choose to reach out via email.

Final Thoughts

No one expected the healthcare giant Baxter International to find itself embroiled in such serious allegations. This situation serves as a reminder of the importance of transparency from public companies and the potential implications for investors. Shareholders, stay informed and vigilant as this case unfolds, as the outcome could set a significant precedent in the realm of corporate accountability in the healthcare sector.